The impact of insulin administration during the mixed meal tolerance test

Diabetic Medicine

Volumn 29, Issue 10, 2012, Pages 1279-1284

  Besser, R E J ^a   Jones, A G ^a   Mcdonald, T J ^a,b   Shields, B M ^a   Knight, B A ^a   Hattersley, A T ^a  

^a UNIVERSITY OF EXETER   (United Kingdom)

^b ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DIAGNOSTIC TEST; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; GOLD STANDARD; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; MAJOR CLINICAL STUDY; MALE; MIXED MEAL TOLERANCE TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGE OF ONSET; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; ENGLAND; FASTING; FEMALE; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MEALS; MIDDLE AGED; YOUNG ADULT;

EID: 84866459727     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2012.03649.x     Document Type: Article

References (22)

1. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type1 diabetes. Diabetes Care 2008; 31: 1966-1971.
2. Greenbaum CJ, Harrison LC. Guidelines for intervention trials in subjects with newly diagnosed type1 diabetes. Diabetes 2003; 52: 1059-1065.
3. Ludvigsson J, Faresjo M, Hjorth M, Axelsson S, Cheramy M, Pihl M et al. GAD treatment and insulin secretion in recent-onset type1 diabetes. N Engl J Med 2008; 359: 1909-1920.
4. Herold KC, Gitelman SE, Masharani U, Hagopian W, Bisikirska B, Donaldson D et al. A single course of anti-CD3 monoclonal antibody hOKT3γ1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2years after onset of Type1 diabetes. Diabetes 2005; 54: 1763-1769.
5. Lazar L, Ofan R, Weintrob N, Avron A, Tamir M, Elias D et al. Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type1 diabetes: a randomised, double-blind phaseII study. Diabetes Metab Res Rev 2007; 23: 286-291.
6. Agardh CD, Cilio CM, Lethagen A, Lynch K, Leslie RD, Palmer M et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005; 19: 238-246.
7. Pitocco D, Crino A, Di Stasio E, Manfrini S, Guglielmi C, Spera S et al. The effects of calcitriol and nicotinamide on residual pancreatic β-cell function in patients with recent-onset Type1 diabetes (IMDIAB XI). Diabet Med 2006; 23: 920-923.
8. Daneman D, Clarson C. Residual beta-cell function in children with type1 diabetes: measurement and impact on glycemic control. Clin Invest Med 1987; 10: 484-487.
9. Schloot NC, Meierhoff G, Lengyel C, Vandorfi G, Takacs J, Panczel P et al. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type1: two prospective, randomized, double-blind phaseII trials. Diabetes Metab Res Rev 2007; 23: 276-285.
10. Nordwall M, Ludvigsson J. Clinical manifestations and beta cell function in Swedish diabetic children have remained unchanged during the last 25years. Diabetes Metab Res Rev 2008; 24: 472-479.
11. Greenbaum CJ, Anderson AM, Dolan LM, Mayer-Davis EJ, Dabelea D, Imperatore G et al. Preservation of beta-cell function in autoantibody-positive youth with diabetes. Diabetes Care 2009; 32: 1839-1844.
12. Gjessing HJ, Matzen LE, Froland A, Faber OK. Correlations between fasting plasma C-peptide, glucagon-stimulated plasma C-peptide, and urinary C-peptide in insulin-treated diabetics. Diabetes Care 1987; 10: 487-490.
13. Hendriksen C, Faber OK, Drejer J, Binder C. Prevalence of residual B-cell function in insulin-treated diabetics evaluated by the plasma C-peptide response to intravenous glucagon. Diabetologia 1977; 13: 615-619.
14. The DCCT Research Group. Effects of age, duration and treatment of insulin-dependent diabetes mellitus on residual beta-cell function: observations during eligibility testing for the Diabetes Control and Complications Trial (DCCT). J Clin Endocrinol Metab 1987; 65: 30-36.
15. Faber OK, Binder C. C-peptide response to glucagon. A test for the residual beta-cell function in diabetes mellitus. Diabetes 1977; 26: 605-610.
16. Garcia-Webb P, Bonser A, Welborn TA. Correlation between fasting serum C-peptide and B cell insulin secretory capacity in diabetes mellitus. Diabetologia 1982; 22: 296.
17. McDonald TJ, Colclough K, Brown R, Shields B, Shepherd M, Bingley P et al. Islet autoantibodies can discriminate maturity-onset diabetes of the young (MODY) from Type1 diabetes. Diabet Med 2009; 55: 2035-2039.
18. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type1 diabetes in the Diabetes Control and Complications Trial. A randomized, controlled trial. Ann Intern Med 1998; 128: 517-523.
19. Keymeulen B, Vandemeulebroucke E, Ziegler AG, Mathieu C, Kaufman L, Hale G et al. Insulin needs after CD3-antibody therapy in new-onset type1 diabetes. N Engl J Med 2005; 352: 2598-2608.
20. Raz I, Avron A, Tamir M, Metzger M, Symer L, Eldor R et al. Treatment of new-onset type1 diabetes with peptide DiaPep277 is safe and associated with preserved beta-cell function: extension of a randomized, double-blind, phaseII trial. Diabetes Metab Res Rev 2007; 23: 292-298.
21. Steele C, Hagopian WA, Gitelman S, Masharani U, Cavaghan M, Rother KI et al. Insulin secretion in type1 diabetes. Diabetes 2004; 53: 426-433.
22. Tsai EB, Sherry NA, Palmer JP, Herold KC. The rise and fall of insulin secretion in type1 diabetes mellitus. Diabetologia 2006; 49: 261-270.